- Home
- PRME vs ABUS Comparison
PRME vs ABUS Comparison
Compare PRME & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- ABUS
- Stock Information
- Founded
- PRME 2019
- ABUS 2005
- Country
- PRME United States
- ABUS United States
- Employees
- PRME N/A
- ABUS N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- ABUS Health Care
- Exchange
- PRME Nasdaq
- ABUS Nasdaq
- Market Cap
- PRME 693.5M
- ABUS 711.2M
- IPO Year
- PRME 2022
- ABUS N/A
- Fundamental
- Price
- PRME $4.07
- ABUS $4.46
- Analyst Decision
- PRME Buy
- ABUS Strong Buy
- Analyst Count
- PRME 6
- ABUS 2
- Target Price
- PRME $8.88
- ABUS $5.00
- AVG Volume (30 Days)
- PRME 2.8M
- ABUS 1.5M
- Earning Date
- PRME 11-11-2025
- ABUS 11-05-2025
- Dividend Yield
- PRME N/A
- ABUS N/A
- EPS Growth
- PRME N/A
- ABUS N/A
- EPS
- PRME N/A
- ABUS N/A
- Revenue
- PRME $4,961,000.00
- ABUS $15,416,000.00
- Revenue This Year
- PRME $179.58
- ABUS $138.02
- Revenue Next Year
- PRME N/A
- ABUS N/A
- P/E Ratio
- PRME N/A
- ABUS N/A
- Revenue Growth
- PRME 739.42
- ABUS 53.23
- 52 Week Low
- PRME $1.11
- ABUS $2.71
- 52 Week High
- PRME $5.17
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- PRME 58.95
- ABUS 66.80
- Support Level
- PRME $3.09
- ABUS $4.01
- Resistance Level
- PRME $4.18
- ABUS $5.10
- Average True Range (ATR)
- PRME 0.27
- ABUS 0.25
- MACD
- PRME 0.08
- ABUS 0.09
- Stochastic Oscillator
- PRME 89.91
- ABUS 60.25
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.